PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Products under Development and the Licensing and Due Diligence Processes
From issue 57 of the PharmaDeals Review (2005-03-01)
Nic Scalfarotto of Bristol-Myers Squibb offers a personal perspective. He discusses the reasons for licensing, the associated due diligence and planning, the different stages of the licensing process and where the due diligence process fits into this, and various key roles for due diligence.
Available as PDF
(Subscribers only)
Technology Focus: Cell Therapy
From issue 57 of the PharmaDeals Review (2005-03-01)
Many debilitating conditions result from cell or tissue damage and thus are not amenable to current molecular drug therapies. This feature reviews some of the novel cell therapy approaches that are being explored and considers the types of deals that are being undertaken to accelerate the development of these approaches.
Available as PDF
(Subscribers only)
Ortho-McNeil's Re-Entry into the Diabetes Arena
From issue 56 of the PharmaDeals Review (2005-02-01)
Arena's US$608 M GPCR collaboration agreement with Ortho-McNeil is one of the highest value preclinical deals in biotech's history. Here we analyse the diabetes collaboration, looking at why it was valued so highly and why the alliance may turn out to be broader than it appears on the surface.
Available as PDF
(Subscribers only)
CAT and Abbott: A David and Goliath Story
From issue 56 of the PharmaDeals Review (2005-02-01)
Following a legal victory over Abbott Laboratories, Cambridge Antibody Technology (CAT) will now receive royalties on the rheumatoid arthritis therapeutic Humira® (adalimumab), at a rate more than double the one it was receiving before. This feature considers the significance of the court's verdict both to CAT and the wider biotechnology industry.
Available as PDF
(Subscribers only)
Deal Making in the Biopharmaceutical Sector
From issue 56 of the PharmaDeals Review (2005-02-01)
Biopharmaceuticals comprise a rapidly expanding and increasingly lucrative market, which both pharmaceutical and biotech companies are seeking to exploit through deal making. This article reviews some of the key biologics deals that have been signed in the past year as well as the partnering trends that have emerged.
Last Issue PDF
RSS